


Active Filter(s):
Details:
Under the agreement, MabGenesis will apply its unique platform to the discovery of first-in-class candidate antibodies against targets of interest selected by Boehringer Ingelheim.
Lead Product(s): Monoclonal Antibody
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2022